|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Development of an immunomagnetic capture reverse transcription-PCR assay for the detection of Norwalk virus显示文摘 | GILPATRICK S G SCHWAB K J ESTERS M K | 2000 | Journal of Virological Methods2000，90，1： | 1 |
| 2 | The involvement of cysteine proteases and pretease inhibitor genes in the regulation of programmed cell death in plants显示文摘 | MAZAL S Beatrice B Massimo D Ester M Alex L | | 0，，： | 1 |
| 3 | Augmented paper maps:explcring the design space of a mixed reality system 显示文摘 | Paelke V S ester M | 2010 | ISPRS Journal of Photogrammetry and Remote Sensing2010，65，3： | 1 |
| 4 | Characterization of pu- rified bacterial cellulose focused on its use on paper restora- tion 显示文摘 | Sara M S Jose M C Ester Q | 2015 | Carbohydr Polym2015，116，： | 1 |
| 5 | Characterization of purified bac- terial cellulose focused on its use on paper restoration 显示文摘 | SARA M S JOS? M C ESTER Q | 2015 | Carbohydr Polym2015，116，： | 1 |
| 6 | Characterization of purified bacterial cellulose focused on its use on paper restoration 显示文摘 | Sara M S Jos6 M C Ester Q | 2015 | Carbohydr Polyrn2015，116，： | 1 |
| 7 | Analysis of27polycyclic aromatic hydrocarbons by matrix solid phase dispersion and isotope dilution gas chromatography-mass spectrometry in sewage sludge from the Spanish area of Madrid显示文摘 | Sánchez-Brunete C Ester M | 2007 | Journal of Chromatography A2007，1148，2： | 1 |
| 8 | Cell death effects of resin-based dental material compounds and mercurials in human gingival fibroblasts显示文摘 | Reichl FX Esters M Simon S | 2006 | Arch Toxicol2006，80，6： | 1 |
| 9 | Cel death effects of resin-based dental material compounds and mercurials in human gingival fibroblasts显示文摘 | Reichl FX Esters M Simon S | | 0，，06： | 1 |
| 10 | Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting显示文摘AIM To investigated the real-world effectiveness and safety of various regimens of interferon-free treatments in patients infected with hepatitis C virus(HCV).METHODS We performed an observational study to analyze different antiviral treatments administered to 462 HCV-infected patients, of which 56.7% had liver cirrhosis. HCV RNA after 4 wk of treatment and at 12 wk after treatment sustained virologic response(SVR) as well as serious adverse events(SAEs) was analyzed first for the whole cohort and then separately in patients who met or did not meet the inclusion criteria of a clinical trial(CT-met and CT-unmet, respectively).RESULTS The most frequently prescribed treatment was simeprevir/sofosbuvir(36.4%), followed by sofosbuvir/ledipasvir(24.9%) and ombitasvir/paritaprevir/ritonavir(r)/dasabuvir(19.9%). Ribavirin(RBV) was administered in 198 patients(42.9%). SVRs occurred in 437/462 patients(94.6%). The SVRs ranged between 93.3% and 100% for genotypes 1-4. SVRs were achieved in 96.2% patients in the CTmet group vs 91.9% patients in the CT-unmet group(P = 0.049). Undetectable HCV RNA at week 4 occurred in 72.9% of the patients. In the univariate analysis, the factors associated with SVRs were lower liver stiffness, absence of cirrhosis, higher platelet count, higher albumin levels, no RBV dose reduction, undetectable HCV RNA at week 4 and CT-met group. In the multivariate analysis, only albumin was an independent predictor of treatment failure(P = 0.04). Eleven patients(2.4%) developed SAEs; 5.2% and 0.7% of the patients in the CT-unmet and CT-met groups, respectively(P = 0.003).CONCLUSION A high proportion of patients with HCV infection achieved SVRs. For patients who did not meet the CT criteria, treatment regimens must be optimized. | Huascar Ramos Pedro Linares Ester Badia Isabel Martín Judith Gómez Carolina Almohalla Francisco Jorquera Sara Calvo Isidro García Pilar Conde Begona álvarez Guillermo Karpman Sara Lorenzo Visitación Gozalo Mónica Vásquez Diana Joao Marina de Benito Lourdes Ruiz Felipe Jiménez Federico Sáez-Royuela 无 | 2017 | World Journal of Gastrointestinal Pharmacology and Therapeutics2017，8，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员